ECSP22098041A - Inhibidores alostéricos de egfr y métodos de uso de estos - Google Patents

Inhibidores alostéricos de egfr y métodos de uso de estos

Info

Publication number
ECSP22098041A
ECSP22098041A ECSENADI202298041A ECDI202298041A ECSP22098041A EC SP22098041 A ECSP22098041 A EC SP22098041A EC SENADI202298041 A ECSENADI202298041 A EC SENADI202298041A EC DI202298041 A ECDI202298041 A EC DI202298041A EC SP22098041 A ECSP22098041 A EC SP22098041A
Authority
EC
Ecuador
Prior art keywords
methods
egfr inhibitors
allosteric egfr
compounds
allosteric
Prior art date
Application number
ECSENADI202298041A
Other languages
English (en)
Inventor
Thomas Gero
Steve Stroud
Tyler Beyett
David Heppner
Shih-Chung Huang
Krista E Gipson
David A Scott
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of ECSP22098041A publication Critical patent/ECSP22098041A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La descripción se refiere a compuestos que actúan como inhibidores alostéricos del receptor del factor de crecimiento epidérmico (EGFR); composiciones farmacéuticas que comprenden los compuestos; y métodos para tratar o prevenir trastornos mediados por quinasas, incluido el cáncer y otras enfermedades de proliferación.
ECSENADI202298041A 2020-06-09 2022-12-28 Inhibidores alostéricos de egfr y métodos de uso de estos ECSP22098041A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063036622P 2020-06-09 2020-06-09
US202063111429P 2020-11-09 2020-11-09

Publications (1)

Publication Number Publication Date
ECSP22098041A true ECSP22098041A (es) 2023-06-30

Family

ID=78846544

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202298041A ECSP22098041A (es) 2020-06-09 2022-12-28 Inhibidores alostéricos de egfr y métodos de uso de estos

Country Status (16)

Country Link
US (1) US20230212171A1 (es)
EP (1) EP4161516A4 (es)
JP (3) JP7785701B2 (es)
KR (1) KR20230033645A (es)
CN (1) CN115811977A (es)
AU (1) AU2021289729A1 (es)
BR (1) BR112022025139A2 (es)
CA (1) CA3181982A1 (es)
CO (1) CO2022019316A2 (es)
EC (1) ECSP22098041A (es)
IL (1) IL298935A (es)
JO (1) JOP20220332A1 (es)
MX (1) MX2022015739A (es)
NZ (1) NZ795548A (es)
SA (1) SA522441639B1 (es)
WO (1) WO2021252661A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250025439A (ko) * 2022-06-21 2025-02-21 다나-파버 캔서 인스티튜트 인크. 융합된 비시클릭 egfr 억제제 및 그의 사용 방법
GB202216962D0 (en) 2022-11-14 2022-12-28 Addex Pharmaceuticals Sa Novel compounds
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005021963A1 (de) * 2005-05-12 2006-11-23 Aicuris Gmbh & Co. Kg Substituierte Dihydropyrazolotriazinone
WO2008079787A2 (en) * 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
CN102015677A (zh) * 2007-04-20 2011-04-13 先灵公司 嘧啶酮衍生物及其使用方法
EP2376492B1 (en) * 2008-09-19 2015-04-08 Nerviano Medical Sciences S.r.l. 3,4 DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES
CA2987914C (en) * 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
BR112020026450A2 (pt) * 2018-06-29 2021-03-23 F. Hoffmann-La Roche Ag Compostos de fórmula i
CN112839937B (zh) * 2018-08-16 2023-08-22 韩国化学研究院 异吲哚啉-1-酮衍生物、其制备方法及其用途

Also Published As

Publication number Publication date
JP7785701B2 (ja) 2025-12-15
EP4161516A4 (en) 2024-08-07
KR20230033645A (ko) 2023-03-08
JP2023529701A (ja) 2023-07-11
IL298935A (en) 2023-02-01
EP4161516A1 (en) 2023-04-12
WO2021252661A1 (en) 2021-12-16
MX2022015739A (es) 2023-03-23
AU2021289729A1 (en) 2023-02-02
CA3181982A1 (en) 2021-12-16
CO2022019316A2 (es) 2023-01-16
NZ795548A (en) 2026-01-30
JP2025168374A (ja) 2025-11-07
SA522441639B1 (ar) 2024-10-24
JOP20220332A1 (ar) 2022-12-08
US20230212171A1 (en) 2023-07-06
JP2025170326A (ja) 2025-11-18
BR112022025139A2 (pt) 2023-02-14
CN115811977A (zh) 2023-03-17

Similar Documents

Publication Publication Date Title
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
MX2025000271A (es) Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades
CO2022006466A2 (es) Inhibidores de egfr alostéricos y métodos de uso de los mismos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
BR112023000654A2 (pt) Composto de pirazolopirimidina usado como inibidor de atr quinase
CR20220299A (es) Derivados de becimidazol
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
CL2023002633A1 (es) Derivados de uracilo como inhibidores de trpa1
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
BR112021020405A2 (pt) Benzo- e pirido-pirazóis como inibidores de proteína quinase
CL2025002032A1 (es) Inhibidores del egfr selectivos de mutantes
CO2022017969A2 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2
DOP2025000274A (es) Inhibidores de egfr para el tratamiento de enfermedades
MX2023007297A (es) 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1.
AR122550A1 (es) Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblatos
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
CR20150593A (es) Potenciador de inhibidores del homólogo de zeste